Multiple Rising Oral Doses of BI 1060469 in Healthy and Mild Asthma Subjects
The primary objective of this trial is to investigate the safety and tolerability of BI 1060469 in healthy male and female subjects after oral administration of repeated rising doses of 3 mg, 10 mg, 25 mg, 75 mg, 150 mg and 250 mg qd. of 1 day followed by 14 days and in asthmatic male and female subjects after oral administration of repeated rising doses of 25 mg and 150 mg qd of 1 day followed by 28 days.
Secondary objectives are the exploration of the pharmacokinetics (PK) including dose proportionality, dose linearity after single and multiple dose segments, pharmacodynamics (PD) of BI 1060469 and to describe the PK/PD relationship.
|Study start date||2014-04-28|